Email This Article
Headlines & Perspectives
After Exubera, Uncertainty Reigns
By
Robert Steyer
10/22/07 - 04:01 PM EDT
Pfizer's decision to drop inhaled insulin could dim the prospects for competing products.
The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,414.14 | 1,114.05 | 2,237.66 | 36.82 |
Oil *
72.73
|
|
UP
85.25
|
UP
11.58
|
UP
25.97
|
UP
1.36
|
10 Yr
3.68%
SPDR Gold
106.95
|
|
+0.83%
|
+1.05%
|
+1.17%
|
+3.84%
|
Data delayed 20 minutes |
Connect with TheStreet